PRESS RELEASE published on 06/26/2025 at 07:30, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics achieves significant milestone with new manufacturing partnership with Catalent, successfully transferring upstream phase of LUMEVOQ® manufacturing process Gene Therapy GenSight Biologics LUMEVOQ Catalent Manufacturing Partnership
BRIEF published on 05/13/2025 at 22:05, 1 year 6 months ago GenSight Biologics Shareholders Approve Majority of Board's Resolutions Shareholder Meeting Board Resolutions GenSight Biologics LUMEVOQ® Phase III RECOVER
PRESS RELEASE published on 05/13/2025 at 22:00, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics announces approval of all resolutions at Combined General Meeting on May 13, 2025. Company highlights achievements of 2024 and strategic priorities for 2025 Strategic Priorities Approval Combined General Meeting GenSight Biologics Achievements
BRIEF published on 04/23/2025 at 20:35, 1 year 6 months ago GenSight Biologics Announces Annual General Meeting Details Annual General Meeting Shareholders Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 04/23/2025 at 20:30, 1 year 6 months ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 13, 2025 at 2:00 pm CEST in Paris, France. Procedures for obtaining preparatory documents outlined Annual General Meeting Preparatory Documents GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 04/08/2025 at 07:51, 1 year 7 months ago GenSight Biologics Files its 2024 Universal Registration Document AMF Gene Therapy Registration Document GenSight Biologics Retina
BRIEF published on 04/08/2025 at 07:48, 1 year 7 months ago GenSight Biologics Files 2024 Universal Registration Document Universal Registration Document GenSight Biologics Gene Therapies Retinal Diseases Financial Report 2024
PRESS RELEASE published on 04/08/2025 at 07:43, 1 year 7 months ago INSIDE INFORMATION / OTHER NEWS RELEASES GenSight Biologics announces the filing of its 2024 Universal Registration Document with the French market authority, including financial reports and corporate governance details GenSight Biologics Gene Therapies Retinal Neurodegenerative Diseases 2024 Universal Registration Document Central Nervous System Disorders
BRIEF published on 04/07/2025 at 20:19, 1 year 7 months ago GenSight Biologics Financial and Business Update Fundraising Clinical Trials Gene Therapy Financial Update GenSight Biologics
PRESS RELEASE published on 04/07/2025 at 20:14, 1 year 7 months ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and business update as of March 31, 2025. Discussions with French agency progressing. Fundraising planned for Phase III trial and marketing advancement Business Update Cash Position Fundraising Activities GenSight Biologics RECOVER Phase III Trial
Published on 11/20/2026 at 15:00, 1 day 13 hours ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 1 day 13 hours ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 1 day 14 hours ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 1 day 15 hours ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 1 day 15 hours ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 1 day 4 hours ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 21:36, 1 day 7 hours ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 19:26, 1 day 9 hours ago EQS-Adhoc: TAKKT AG: TAKKT revises its 2026 full-year forecast following the cyberattack
Published on 11/20/2026 at 19:03, 1 day 9 hours ago EQS-Adhoc: Allgeier SE confirms rumors regarding sale process for the Evora Group
Published on 11/20/2026 at 18:34, 1 day 10 hours ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 1 day 11 hours ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 2 days 9 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 08:30, 2 days 20 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing